Comment from Prime Therapeutics

Summary: Prime Therapeutics LLC supports the FDA's proposed CNPV Pilot Program as a way to accelerate access to innovative therapies and strengthen the supply chain. However, they request greater transparency regarding the selection process, clearer definitions of national health priorities, and a dedicated website to track post-marketing commitments and program outcomes.